The high-risk variant, ApoE4, triggers an inflammatory reaction that weakens the blood-brain barrier, a network of cells and other components that lines brain vessels, which would normally create a barrier to nutrients into the brain and keep harmful substances out, according to a study published May 16 in Nature. Researchers have found that in mice, having the most risky variant of ApoE damages the blood vessels that feed the brain.
The Canadian Minister of Health, Leona Aglukkaq, has announced that the government will invest heavily in neuroscience research by creating the Canada Brain Research Fund.
The World Health Organization (WHO) and Alzheimer's Disease International (ADI) released a report April 11 calling for governments and policymakers to make dementia a global public health priority. The report provides an overview of the impact of dementia worldwide, in addition to global best practices and practical case studies.
The FDA has approved Amyvid, a radioactive diagnostic agent from Eli Lilly and Avid Radiopharmaceuticals that is indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
The Alzheimer's Association has awarded its largest research grant—nearly $4.2 million over four years—to the Dominantly Inherited Alzheimer's Network-Therapeutic Trials Unit, based at Washington University School of Medicine in St. Louis, to enable the program to move forward with drug and biomarker trials in people with genetically based, young-onset Alzheimer's disease.
Advanced cancer biomarker research may well be moving beyond the realm of diagnostic to preventive medicine.
The Lawson Health Research Institute in London, Ontario, will install Siemen’s Biograph mMR, a synchronous MR/PET system.
A team of University of California, Los Angeles scientists who developed a chemical marker to help assess the neurological changes associated with cognitive impairment and dementia have found the brain-imaging tool effectively tracked and predicted cognitive decline over a two-year period, according to a study published in the February issue of Archives of Neurology.
Revised criteria for the diagnosis of mild cognitive impairment (MCI) could compromise the diagnosis of Alzheimer disease (AD) dementia, according to an analysis published online Feb. 6 in Archives of Neurology.
TRIUMF, Canada's national laboratory for particle and nuclear physics, has begun building a tunnel and lab that will be used to demonstrate new ways to solve medical isotope shortages.
The Centre for Addiction and Mental Health (CAMH) in Toronto will open the doors to its new Research Imaging Centre, where PET, MRI and genetic imaging will be focused on the study of addictions and mental illness.
Columbia University's engineering researchers have developed a technique that utilizes extremely short pulses of ultrasound waves to open the blood-brain barrier, creating a host of possibilities for noninvasively treating brain disorders such as Alzheimer’s disease, Parkinson’s disease, atypical lobular hyperplasia and epilepsy.
McMaster University in Hamilton, Ontario, has unveiled its newly expanded Nuclear Research Building, which includes a new cyclotron facility and improvements to the McMaster Nuclear Reactor (MNR) Building.
NeuroLogica has received CE Mark approval for its portable inSPira HD SPECT camera.
Individuals with deterministic genes in whom it is known that Alzheimer’s disease (AD) will develop appear to show differences in beta-amyloid distribution when compared with non-dominantly inherited AD patients, helping to consolidate evidence that PET and MRI can depict brain changes well before the arrival of AD-related symptoms, according to preliminary findings presented July 20 at the 2011 Alzheimer’s Association International Conference in Paris.
Known to be significantly more susceptible to dementia, individuals with Down syndrome appear to display age-related increases in amyloid senile plaques and tau neurofibrillary tangles that mirror those increases in Alzheimer’s patients as viewed with PET, according to a study published in the June issue of Archives of Neurology.
A new 3D x-ray method, SAXS-CT, offers detailed images of brain cells and maps the myelin sheaths of nerve cells, which are key to understanding conditions such as multiple sclerosis and Alzheimer's disease, according to Danish research published in the July issue of NeuroImage.
|
RSS 
